follitropin alfa / lutropin alfa

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Pergoveris. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pergoveris.

For practical information about using Pergoveris, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 29/11/2021

Authorisation details

Product details
Agency product number
Active substance
  • follitropin alfa
  • lutropin alfa
International non-proprietary name (INN) or common name
  • follitropin alfa
  • lutropin alfa
Therapeutic area (MeSH)
Infertility, Female
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Europe B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Gustav Mahlerplein 102
Ito Toren
1082 MA Amsterdam
The Netherlands

Product information

14/10/2021 Pergoveris - EMEA/H/C/000714 - II/0075


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (LH) and follicle-stimulating-hormone deficiency.

In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.

Assessment history

How useful was this page?

Add your rating
2 ratings